These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

84 related items for PubMed ID: 11361526

  • 1. Triple therapy in previously untreated patients reduces viral load below limit of detection.
    AIDS Patient Care STDS; 1996 Oct; 10(5):308-9. PubMed ID: 11361526
    [No Abstract] [Full Text] [Related]

  • 2. Viramune triple combo reduces viral load below limit of detection.
    AIDS Patient Care STDS; 1997 Dec; 11(6):456. PubMed ID: 11361870
    [No Abstract] [Full Text] [Related]

  • 3. Viral load--how low is best?
    TreatmentUpdate; 1998 Dec; 10(10):2-3. PubMed ID: 11366016
    [Abstract] [Full Text] [Related]

  • 4. Viramune triple therapy shows suppression of HIV after 1 year, 7 months.
    AIDS Patient Care STDS; 1997 Dec; 11(6):456-7. PubMed ID: 11361871
    [No Abstract] [Full Text] [Related]

  • 5. Nevirapine triple combo results released.
    Common Factor; 1995 Apr; (no 10):21. PubMed ID: 11362346
    [Abstract] [Full Text] [Related]

  • 6. Two studies suggest nevirapine benefit for children.
    AIDS Patient Care STDS; 1997 Jun; 11(3):195. PubMed ID: 11361798
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Therapeutic advantage of hydroxyurea and didanosine combination therapy in patients previously treated with zidovudine.
    Foli A, Maserati R, Minoli L, Wainberg MA, Gallo RC, Lisziewicz J, Lori F.
    AIDS; 1998 Jun 18; 12(9):1113-4. PubMed ID: 9662215
    [No Abstract] [Full Text] [Related]

  • 10. Maintaining a low viral load with Nevirapine?
    TreatmentUpdate; 1998 Dec 18; 10(10):3-4. PubMed ID: 11366017
    [Abstract] [Full Text] [Related]

  • 11. Nevirapine surprise.
    Smart T.
    GMHC Treat Issues; 1996 Dec 18; 10(6/7):25. PubMed ID: 11363640
    [Abstract] [Full Text] [Related]

  • 12. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM, Chêuc G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T, Decazes JM, ALBI (ANRS 070) Study Group.
    Antivir Ther; 1999 Dec 18; 4 Suppl 3():71-4. PubMed ID: 16021874
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks.
    Paton NI, Aboulhab J.
    HIV Med; 2005 Jan 18; 6(1):13-20. PubMed ID: 15670247
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Researchers report sustained suppression of HIV with nevirapine--didanosine--zidovudine.
    Am J Health Syst Pharm; 1998 Jun 01; 55(11):1106, 1108. PubMed ID: 9626369
    [No Abstract] [Full Text] [Related]

  • 20. Pediatric antiretroviral therapy: from research to practice.
    Farley J, Vink P.
    Pediatr AIDS HIV Infect; 1996 Feb 01; 7(1):9-13. PubMed ID: 11361479
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.